Skip to Main Content

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease (PADOVA)

Conditions

Diseases of the Nervous System

Phase IIIb

What is the purpose of this trial?

This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.

  • Trial with
    Genentech, Inc.
  • Start Date
    06/01/2022
  • End Date
    11/13/2023

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/17/2022
  • Study HIC
    #2000029815